Schizophrenia & Psychotic Disorders

When assessing the value of a reward, people with schizophrenia have difficulty integrating information about the size of the reward and the probability of receiving it, according to a published study.

Articles

Rakesh Jain, MD, MPH

Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.

Normal sex differences in the ability to mentalize are reversed in people with schizophrenia, researchers report.

Frequent cannabis use and psychotic-like experiences (PLEs) seem to be associated with person-specific vulnerabilities, not just genetic factors, researchers say.

ORLANDO, Fla.—Brexpiprazole demonstrated “robust efficacy” in the treatment of patients with schizophrenia who have severe psychotic symptoms, researchers reported at Psych Congress 2018.

ORLANDO, Fla—A novel agent for the treatment of schizophrenia is producing promising results in efficacy and safety trials. Researchers presented an overview of late-stage studies of the drug at Psych Congress 2018.

Pages

Posters

Daisy Ng-Mak, PhD; Andrew Messali, PharmD, PhD; Krithika Rajagopalan, PhD; Joseph Tkacz, MS; Brenna L. Brady, PhD; Charles Ruetsch, PhD; Antony Loebel, MD
John M. Kane, MD; Christoph U. Correll, MD; Nick Delva, MD; Srihari Gopal, MD; Adam Savitz, MD; Maju Mathews, MD
Karen Anderson, MD; Mat Davis, PhD; Stewart Factor, DO; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Hubert Fernandez, MD
Branislav Mancevski, MD; Jagadish Gogate, PhD; Katie Ashcroft, BA, M.Phil D.Clin.Psy; Kristy Tardieu, BSN, MBA; Edward Kim, MD
Willie Earley, MD; Hua Guo, PhD; Balázs Szatmár, MD; György Németh, MD, PhD; Henry Nasrallah, MD; David Daniel, MD; Mehul Patel, PharmD; Chris Gache, MD

Pages

Video

Leslie Citrome, MD, MPH, Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College, highlights what recent research shows regarding the role of glutamate in schizophrenia.

Peter Weiden, MD, and Charles Raision, MD, talk about how to do cognitive behavioral therapy with a group of people who have patterns of cognitive dysfunction. Click here to read the

Mary Anne Lang, MS, RN-BC, talks with Vladimir Maletic, MD, about practical ways to objectively track patients' adherence to antipsychotic medications.

Pages